Trial Profile
Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary) ; Gemcitabine; Paclitaxel; Rivaroxaban
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 03 Jul 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 03 Jul 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 15 Jul 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.